For depression and/or anxiety. ANDA 215076, held by Alembic. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 215076 (Doxepin Hydrochloride), held by Alembic, was first approved by FDA on Apr 21, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2021 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 10MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 25MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 50MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 75MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 100MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Sep 30, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 21, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters